The Hong Kong market has seen a remarkable rebound, with the Hang Seng Index rising 1.99% amid mixed economic signals from China. As global markets show signs of recovery and investor sentiment improves, it is crucial to identify high-growth technology stocks that can capitalize on these trends and offer the potential for significant returns.
The 10 fastest growing technology companies in Hong Kong
name |
Sales growth |
Profit growth |
Growth assessment |
---|---|---|---|
Wasion Holdings |
22.71% |
25.80% |
★★★★★☆ |
Be friends and keep |
33.82% |
32.27% |
★★★★★★ |
MedSci Healthcare Holdings |
45.88% |
45.90% |
★★★★★☆ |
Inspur Digital Enterprise Technology |
21.83% |
38.02% |
★★★★★☆ |
iDreamSky Technology Holdings |
29.81% |
104.11% |
★★★★★★ |
Cowell and Holdings |
30.96% |
35.72% |
★★★★★★ |
RemeGen |
26.30% |
52.19% |
★★★★★☆ |
Innovent Biologics |
21.21% |
50.78% |
★★★★★☆ |
Biocytogen Pharmaceuticals (Beijing) |
21.35% |
100.10% |
★★★★★☆ |
Beijing Airdoc Technology |
31.64% |
83.90% |
★★★★★☆ |
Click here to see the full list of 47 stocks from our SEHK High Growth Tech & AI Stocks Screener.
We examine a selection of our screener results.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Everest Medicines Limited is a biopharmaceutical company focused on the discovery, licensing, development and commercialization of therapies and vaccines for critical unmet medical needs in Greater China and other Asia Pacific markets and has a market capitalization of HK$6.22 billion.
Operations: Everest Medicines Limited generates revenues of CNY 125.93 million primarily from the sale of pharmaceuticals. The company is focused on addressing critical unmet medical needs in Greater China and other Asia Pacific markets through its biopharmaceutical products.
Everest Medicines is making significant strides in biotechnology, particularly with its recent advances in the treatment of autoimmune diseases. The company reported annual revenue growth forecast of 37.8% and expects earnings growth of an impressive 76.3% per year, underscoring solid future prospects. Everest’s significant investment in research and development, totaling $50 million per year, underscores its commitment to innovation. With the successful dosing of zetomipzomib in Phase 2b trials for lupus nephritis and positive data from NEFECON® trials, Everest is poised to make a significant impact on the biotechnology landscape.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Qingci Games Inc., an investment holding company with a market capitalization of HK$2.01 billion, develops, publishes and operates mobile games in various international markets including China, Japan, the United States, Canada, Australia, New Zealand, Hong Kong, Macau and Taiwan.
Operations: Qingci Games generates its revenue primarily through the development, publishing and operation of mobile games. For the most recent period, the company reported revenue of CN¥905.74 million from its computer graphics segment.
Qingci Games is experiencing rapid growth, with revenue expected to grow by 40.1% annually, significantly outperforming the Hong Kong market at 7.4%. The company’s earnings are expected to grow by an impressive 111.7% per year over the next three years, underscoring its profitability potential despite its current unprofitability. In particular, Qingci Games has invested heavily in research and development, which amounted to $30 million last year, underscoring its commitment to innovation and long-term growth in the competitive gaming industry.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Beisen Holding Limited, an investment holding company with a market capitalization of HK$2.61 billion, provides cloud-based human capital management solutions for enterprises in the People’s Republic of China to recruit, assess, manage, develop and retain talent.
Operations: Beisen Holding generates revenues primarily from the provision of cloud-based human capital management (HCM) solutions and related professional services totaling CN¥854.74 million. The company’s business focuses on providing tools for enterprises to manage their talent lifecycle in the People’s Republic of China.
Beisen Holding has shown significant growth. Revenue increased from ¥750.91 million to ¥854.74 million last year, a notable increase of 13.8%. Despite a net loss of ¥3,208.59 million due to higher stock-based payments and changes in the fair value of redeemable convertible preferred stock, the company’s annual recurring revenue increased 15-18% to ¥766.9 million, reflecting a strong subscriber retention rate of between 105% and 107%. In addition, Beisen invested heavily in research and development. Expenses accounted for about 15% of total revenue last year, underscoring its commitment to innovation in the technology sector.
Take advantage of the opportunity
Would you like to explore some alternatives?
This Simply Wall St article is of a general nature. We comment solely on the basis of historical data and analyst forecasts, using an unbiased methodology. Our articles do not constitute financial advice. It is not a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our goal is to provide you with long-term analysis based on fundamental data. Note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Simply Wall St does not hold any of the stocks mentioned.
The companies discussed in this article include SEHK:1952, SEHK:6633 and SEHK:9669.
Do you have feedback on this article? Are you interested in the content? Contact us directly. Alternatively, send an email to [email protected]